Showing Results for: “diabetes”

American Diabetes Association Pushes for Federal Policy Change to Remove Systemic Barriers to Health Care Equity and Access The American Diabetes Association ® (ADA) this week urged immediate action to help rectify system-wide hurdles to health and well-being before the Senate Health, Education, Labor and Pensions (HELP) Committee. In a statement for the congressional record, submitted in conjunction with last week’s subcommittee hearing on life expectancy disparities, the ADA spoke to the unique structural challenges faced by Americans with diabetes and stressed the need for federal policy

First-of-its-Kind Data Underscore Importance of Early Use of Drug Therapy as a Primary Prevention, Especially for Those Living with Diabetes Today, a new trial revealed data on the effects of bempedoic acid – a non-statin cholesterol-lowering drug – on cardiovascular outcomes, demonstrating that patients with risk factors for coronary artery disease (CAD) and high cholesterol, particularly those with diabetes, should be treated with a cholesterol-lowering drug. The results were presented as a late-breaking poster at the 83rd Scientific Sessions of the American Diabetes Association ® (ADA) in

State joins growing list helping those living with diabetes afford life-saving medication The American Diabetes Association ® (ADA) applauds Rhode Island Governor Daniel McKee for signing legislation capping monthly copayments for insulin at $40 for those on state-regulated plans, making Rhode Island the 20th state, plus the District of Columbia, to enact a copay cap on the life-saving medication. Speaker Pro Tempore Brian Patrick Kennedy and Senator Melissa Murray steered the legislation, with support from Representatives Morales and Diaz, to favorable passage in the House and Senate. “This

Data reveals potential for once-daily oral and monthly injectable treatment alternatives for patients with type 2 diabetes and obesity Findings from two breakthrough studies reveal positive outcomes for two medications - orfoglipron and MariTide (maridebart cafraglutide) – expanding the treatment of type two diabetes and obesity. Results from the ACHIEVE-1 Trial and the MariTide Phase 2 Trial were simultaneously published in the New England Journal of Medicine (NEJM) and presented as late-breaking symposia at the American Diabetes Association’s® (ADA) 85th Scientific Sessions in Chicago. As of

Embargoed until Sunday, June 7, 2026, at 4:30 p.m. CT Findings Demonstrate Potential for Amylin and GLP-1 Combinations as Next Generation of Weight Loss and Diabetes Treatment New international study findings demonstrated positive results of the first injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) and amylin analogue combination treatment in improving blood glucose control and supporting weight loss across diverse populations of adults living with type 2 diabetes. Researchers presented data on the REIMAGINE clinical trials as a symposium at the 2026 Scientific Sessions of the

Breakthrough Studies Demonstrate Stem Cell-Based Technologies as a Potential Alternative Treatment for Type 1 Diabetes Findings from two studies reveal advancements in stem cell-derived treatment options to treat type 1 diabetes. Results from the FORWARD study, also simultaneously published in the New England Journal of Medicine ( NEJM), evaluating the first and only allogeneic, stem-cell derived, islet cell therapy and a study of genetically modified stem cells were unveiled as an oral presentation and late-breaking poster, respectively, at the 85th Scientific Sessions of the American

The American Diabetes Association® (ADA), announced today that Chief Executive Officer Tracey D. Brown will be leaving the ADA effective October 6, 2021, to take a senior leadership role at Walgreens as President of Retail Products and Chief Customer Officer. Under Brown’s tenure ADA, the nation’s largest voluntary health organization and global authority on diabetes, increased the amount raised and invested in diabetes research, continuing to improve health outcomes for people living with diabetes, while strengthening the organization’s financial footing. Brown built upon the ADA’s historic

American Diabetes Association Symposium to Highlight Once Weekly Drug as Potential Treatment for Obesity Today, findings from SURMOUNT-1, the first investigational phase 3 trial evaluating the safety and efficacy of tirzepatide for the treatment of obesity, were announced, representing a new class of medicines being studied for the treatment of obesity. The trial was presented at a symposium at the 82nd Scientific Sessions of the American Diabetes Association ® (ADA) in New Orleans, LA, and simultaneously published in The New England Journal of Medicine. Obesity impacts 650 million people

Call for Action from ADA Community Results in House-Supported Co-Pay Cap The American Diabetes Association ® (ADA) hailed a major national victory today when the U.S. House of Representatives passed the Build Back Better Act, including the most sweeping nationwide measure to date to limit out-of-pocket co-pays for insulin. The national co-pay cap, which ADA has aggressively promoted, would apply to Medicare beneficiaries, individuals on commercial insurance, and those covered by other group health plans. The House-passed legislation creates an out-of-pocket co-pay limit of $35 per month for

The American Diabetes Association® applauds the New Mexico governor and legislature for passing HB 292 Today, Governor Michelle Lujan Grisham of New Mexico signed legislation capping monthly copayments for insulin at $25, making New Mexico the third state to enact a co-pay cap—with the lowest dollar amount for a co-pay cap introduced at the state level to date. Insulin affordability is a critical issue facing millions of Americans, with the price of insulin nearly tripling between 2002 and 2013. The American Diabetes Association (ADA) applauds Governor Michelle Lujan Grisham and bill sponsors